当前位置:

网站首页>文章详情

替格瑞洛对冠心病患者血浆内脂素、血清氧化应激标志物水平及疗效的影响

【PDF在线阅读】 【下载PDF】
  • Author:

  • Author Unit:

  • Keywords:

摘要:

目的 探讨替格瑞洛对冠状动脉粥样硬化性心脏病(冠心病)患者血浆内脂素、血清氧化
应激标志物水平及疗效的影响。方法 选择2015年9月至2017年9月于西安交通大学第二附属医院收治的
冠心病患者95例,随机分为观察组(n=48)和对照组(n=47)。对照组给予常规氯吡格雷治疗,观察
组为替格瑞洛治疗,其他治疗方案两组相同,干预时间均为12周。治疗结束后比较两组患者血浆内脂
素、血清氧化应激标志物水平、疗效及不良反应的发生情况。结果 治疗后,观察组总有效率89.58%,
高于对照组的70.21%(P<0.05);两组治疗后的晚期蛋白质氧化产物(AOPP)、超氧化物歧化酶
(SOD)、丙二醛(MDA)和晚期糖基化终末产物(AGEs)水平比较,观察组均显著优于对照组(P
<0.01);观察组治疗后的血浆内脏脂肪素水平显著低于对照组(P<0.01)。观察组不良反应发生率为
6.25%;对照组为21.28%,观察组不良反应发生率明显低于对照组(P<0.05)。结论 在冠心病患者中
应用替格瑞洛治疗效果显著,可有效改善血浆内脂素、血清氧化应激标志物水平,减少不良反应。

Abstract:

Objective To discuss the influence of ticagrelor on levels of plasma visfatin and serum oxidative
stress biomarkers and curative effect in patients with coronary heart disease (CHD). Methods CHD patients (n=95)
were chosen from the Second Affiliated Hospital of Xi’an Jiaotong University from Sept. 2015 to Sept. 2017, and then
divided randomly into observation group (n=48) and control group (n=47). Besides of the same therapeutic schemes,
the control group was conventionally treated with clopidogrel and observation group was treated with ticagrelor for 12
weeks. The levels of plasma visfatin and serum oxidative stress biomarkers, curative effect and incidence of adverse
reactions were compared between 2 groups after the treatment finished. Results The total effective rate was 89.58%
in observation group and 70.21% in control group (P<0.05). The comparisons in levels of advanced oxidation protein
product (AOPP), superoxide dismutase (SOD), malondialdehyde (MDA) and advanced glycation end products (AGEs)
showed that observation group was significantly superior to control group after treatment (P<0.01). The level of plasma
visfatin was significantly lower in observation group than that in control group after treatment (P<0.01). The incidence
rates of adverse reactions were 6.25% in observation group and 21.28% in control group (P<0.05). Conclusion
Ticagrelor has significant curative effect, and it can effectively improve the levels of plasma visfatin and serum oxidative
stress biomarkers and reduce adverse reactions in CHD patients.

基金项目:

参考文献:

[1] 鲁爱慧,林仙方. 三维斑点追踪超声心动图评价冠状动脉粥样硬
化性心脏病的应用进展[J]. 临床超声医学杂志,2017,19(3):190-2.
[ 2 ] 潘媛媛,彭羽. 循证护理对老年冠状动脉粥样硬化性心脏
病患者生活质量和心理状况的影响[ J ] . 实用医院临床杂
志,2017,14(2):99-102.
[3] Emdin CA,Khera AV,Natarajan P,et al. Genetic association of waistto-
hip ratio with cardiometabolic traits, type 2 diabetes and coronary
heart disease[J]. Jama,2017,317(6):626-34.
[4] 孙桂强,张文龙,王文,等. 卡维地洛治疗无心梗冠心病患者心绞痛
的临床疗效观察[J]. 重庆医学,2017,46(2):241-3.
[5] 孙喜文,张灿,林秋伟. 替格瑞洛在急性冠脉综合征患者介入治疗
中的应用效果[J]. 中国循证心血管医学杂志,2017,9(1):102-4.
[6] Geismar K,Enevold C,S?rensen LK,et al. Involvement of Interleukin-1
Genotypes in the Association of Coronary Heart Disease With
Periodontitis[J]. Journal of Periodontology,2017,79(12):2322-30.
[7] 王馨,张琳,张晓东,等. 急性冠状动脉综合征患者血浆网膜素-1、
内脏脂肪特异性丝氨酸蛋白酶抑制剂水平变化[J]. 中国循环杂
志,2016,31(5):446-8.
[8] 陈富荣. 冠状动脉粥样硬化性心脏病的预防诊断与治疗现状[J].
新医学,2005,36(11):626-7.
[9] Dale CE,Fatemifar G,Palmer TM,et al. Causal Associations of
Adiposity and Body Fat Distribution With Coronary Heart Disease,
Stroke Subtypes, and Type 2 Diabetes Mellitus:A Mendelian
Randomization Analysis[J]. Circulation,2017,135(24):2373.
[10] 郭旋,韩清华. 替格瑞洛的多效性及其作用机制的研究进展[J]. 中
国医药,2018,13(3):464-6.
[11] 鄂璐莎. 冠状动脉介入治疗患者口服替格瑞洛的疗效观察[J]. 中
国医药,2018,13(2):165-8.
[12] 付明明,陆健. 替格瑞洛结合瑞舒伐他汀用于不稳定型心绞痛治
疗的疗效分析[J]. 河北医学,2017,23(6):935-7.
[13] Campo G,Vieceli DSF,Pavasini R,et al. Biological effects of ticagrelor
over clopidogrel in patients withstable coronary artery disease and
chronic obstructive pulmonary disease[J]. ThrombHaemost,2017,117
(06):1208-16.
[14] 刘虹宏,刘兆川,张誉籍,等.替格瑞洛联合重组人脑利钠肽对急性
心肌梗死患者经皮冠状动脉介入术后微循环改善及心肌损伤标
志物的影响[J].中国医药,2019,14(3):330-4.
[15] 王爽,郑秀艳,孙文华,等. 阿托伐他汀联合依折麦布对冠心病患者
氧化应激及血脂水平的影响[J]. 现代生物医学进展,2017,17(13):
2470-3.
[16] 薛玉刚,王翅遥,尚福军,等. 芪参益气滴丸联合薯蓣皂苷片治疗冠
心病心绞痛的临床研究 [J]. 现代药物与临床,2017,32(10):1832-5.
[17] 李佩,刘鹏,张鹏,等. 芪参益气滴丸联合曲美他嗪治疗慢性心力
衰竭患者疗效观察及对其心肌和血脂的影响研究[J]. 世界中医
药,2017,12(8):1812-5.
  • 2008

  • 1

通讯地址:北京市东城区东四十条南门仓5号
电话: 237499284 邮编:100700
网址:www.ebcvm..org Email: ebcvm_cj@126.com

copyright © 《中国循证心血管医学杂志》编辑部
当您在使用本网站投稿遇到困难时,
请直接将稿件投送到编辑部邮箱ebcvm_cj@126.com